In studies of erlotinib resistance in NSCLC cells, OTU domain-containing 1 (OTUD1) enhances cellular sensitivity to erlotinib by inhibiting YAP1 nuclear translocation, accompanied by the inactivation of the SOX9/secreted phosphoprotein 1 pathway (72,73). Here, SOX9 is linked to non-small cell lung carcinoma.